Advanced Neurosciences Research, LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$131,314	55
2024	Research	$52,128	9
2023	Research	$266,483	15
2022	Research	$177,203	10
2021	Research	$3,717	1
2020	Research	$488,673	7
2019	Research	$218,600	12

Breakdown

Who paid Research payments · program years 2019–2025

Biogen, Inc. $471,065 6 payments
Alexion Pharmaceuticals, Inc. $333,032 12 payments
AbbVie, Inc. $218,600 12 payments
TG Therapeutics, Inc. $112,800 21 payments
Genentech, Inc. $82,196 6 payments
Ipsen Innovation $78,527 45 payments
Celgene Corporation $40,591 6 payments
F. Hoffmann-La Roche AG $1,308 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration $302,001 2 payments
A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) $285,764 5 payments
M18-918 $136,738 7 payments
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab $112,800 21 payments
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) $110,390 2 payments
Ensemble $82,196 6 payments
M14-397 $81,862 5 payments
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults $78,527 45 payments
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) $51,660 1 payment
Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis $34,579 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.